Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study

BACKGROUND: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed the risk of these events and the overall survival (OS) benefit in breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Pineda-Moncusí, Marta, Garcia-Giralt, Natalia, Diez-Perez, Adolfo, Tusquets, Ignasi, Servitja, Sonia, Albanell, Joan, Prieto-Alhambra, Daniel, Nogués, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097872/
https://www.ncbi.nlm.nih.gov/pubmed/32231712
http://dx.doi.org/10.1177/1758835920909660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097872/
https://www.ncbi.nlm.nih.gov/pubmed/32231712
http://dx.doi.org/10.1177/1758835920909660

Ejemplares similares